A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas

Trial Profile

A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
    • 26 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Nov 2015 Status changed from recruiting to not yet recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top